# Emcure Pharmaceuticals (NSE: EMCURE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/EMCURE · Pivot · prices to 21 Oct 2026

Emcure Pharmaceuticals (NSE: EMCURE) closed at ₹1,736.10 on 21 Oct 2026. With a market capitalisation of ₹33,551 Cr, it ranks 252nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Packaging & Containers.

At its last close the stock traded at 145.9× trailing earnings, against a return on equity of 18.7% in FY26. Over the past year the share price has risen 24.6%. Its 52-week range is ₹1,306.50 (4 Nov 2025) to ₹2,100.70 (18 Sep 2026); the last close is 17.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹2,580 Cr (+22.8% year on year) and net profit ₹292 Cr (+36.2%), on a consolidated basis. Promoters held 77.83% of the company as of 30 Jun 2026; 0.04% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,736.10 |
| Market cap | ₹33,551 Cr |
| P/E (trailing) | 145.9 |
| ROE | 18.7% (FY26) |
| ROCE | 25.7% (FY26) |
| Debt to equity | 0.24 |
| 52-week high | ₹2,100.70 (18 Sep 2026) |
| 52-week low | ₹1,306.50 (4 Nov 2025) |
| 1-year return | +24.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹2,580 Cr | +22.8% | ₹292 Cr | +36.2% | ₹15.50 |
| Q4 FY26 | ₹2,470 Cr | +16.7% | ₹244 Cr | +23.6% | ₹12.84 |
| Q3 FY26 | ₹2,363 Cr | +20.4% | ₹231 Cr | +48.2% | ₹12.16 |
| Q2 FY26 | ₹2,270 Cr | +13.4% | ₹251 Cr | +24.7% | ₹12.85 |
| Q1 FY26 | ₹2,101 Cr | +15.7% | ₹215 Cr | +40.8% | ₹10.92 |
| Q4 FY25 | ₹2,116 Cr | +19.5% | ₹197 Cr | +63.0% | ₹9.97 |
| Q3 FY25 | ₹1,963 Cr | +23.3% | ₹156 Cr | +30.3% | ₹8.12 |
| Q2 FY25 | ₹2,002 Cr | +20.4% | ₹202 Cr | +38.2% | ₹10.33 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹9,204 Cr | ₹941 Cr |
| FY25 | ₹7,896 Cr | ₹707 Cr |
| FY24 | ₹6,658 Cr | ₹528 Cr |
| FY23 | ₹5,986 Cr | ₹562 Cr |
| FY22 | ₹5,855 Cr | ₹703 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 77.83%
- Foreign institutions: 4.88%
- Domestic institutions: 8.46%
- Non-institutions: 8.83%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Ajanta Pharma](https://app.pivotnow.in/stock/AJANTPHARM) | ₹3,296.00 | ₹41,179 Cr | 39.1 | — |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | ₹1,732.90 | ₹35,414 Cr | 43.5 | — |
| [Global Health](https://app.pivotnow.in/stock/MEDANTA) | ₹1,230.00 | ₹33,071 Cr | 59.6 | — |
| [Wockhardt](https://app.pivotnow.in/stock/WOCKPHARMA) | ₹1,904.90 | ₹30,953 Cr | 146 | — |
| [Dr. Lal Path Labs](https://app.pivotnow.in/stock/LALPATHLAB) | ₹1,830.10 | ₹30,679 Cr | 57.8 | — |
| [Sai Life Sciences](https://app.pivotnow.in/stock/SAILIFE) | ₹1,391.00 | ₹29,529 Cr | 84.8 | — |

## Questions and answers

### What is the share price of Emcure Pharmaceuticals today?

Emcure Pharmaceuticals (NSE: EMCURE) last closed at ₹1,736.10 on 21 Oct 2026. Its 52-week high is ₹2,100.70 and its 52-week low is ₹1,306.50.

### What is the market cap of Emcure Pharmaceuticals?

Emcure Pharmaceuticals' market capitalisation is ₹33,551 Cr (₹33,551 Cr) at the 19 Oct 2026 close, ranking 252nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Emcure Pharmaceuticals?

Emcure Pharmaceuticals trades at a trailing P/E of 145.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 59.6.

### What is the ROE and ROCE of Emcure Pharmaceuticals?

Return on equity was 18.7% in FY26 and return on capital employed was 25.7% in FY26 (consolidated figures).

### Is Emcure Pharmaceuticals a debt-free company?

No. Emcure Pharmaceuticals' debt-to-equity ratio was 0.24 in FY26, with total debt of ₹252 Cr.

### What were Emcure Pharmaceuticals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Emcure Pharmaceuticals reported revenue of ₹2,580 Cr, +22.8% year on year, and net profit of ₹292 Cr, +36.2% year on year.

### How has Emcure Pharmaceuticals stock performed over the last year?

Emcure Pharmaceuticals' share price has risen 24.6% over the past year, −5.0% over three months and −7.3% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Emcure Pharmaceuticals?

As of 30 Jun 2026: promoters 77.83%, foreign institutions 4.88%, domestic institutions 8.46%, non-institutions 8.83%. 0.04% of promoter shares were pledged.

### Who are Emcure Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Emcure Pharmaceuticals by market cap are Ajanta Pharma, Narayana Hrudayalaya, Global Health, Wockhardt, Dr. Lal Path Labs and Sai Life Sciences.

### Is Emcure Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Emcure Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EMCURE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.